FCCC LOGO Faculty Publications
Domchek SM , Friebel TM , Singer CF , Evans DG , Lynch HT , Isaacs C , Garber JE , Neuhausen SL , Matloff E , Eeles R , Pichert G , Van T'veer L , Tung N , Weitzel JN , Couch FJ , Rubinstein WS , Ganz PA , Daly MB , Olopade OI , Tomlinson G , Schildkraut J , Blum JL , Rebbeck TR
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
JAMA-Journal of the American Medical Association. 2010 Sep;304(9) :967-975
Back to previous list
Context Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. Objective To estimate risk and mortality reduction stratified by mutation and prior cancer status. Design, Setting, and Participants Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009. Main Outcomes Measures Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality. Results No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, womenwho underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancerspecific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancerspecific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]). Conclusions Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality. JAMA. 2010; 304(9): 967-975 www.jama.com
Domchek, Susan M. Friebel, Tara M. Singer, Christian F. Evans, D. Gareth Lynch, Henry T. Isaacs, Claudine Garber, Judy E. Neuhausen, Susan L. Matloff, Ellen Eeles, Rosalind Pichert, Gabriella Van T'veer, Laura Tung, Nadine Weitzel, Jeffrey N. Couch, Fergus J. Rubinstein, Wendy S. Ganz, Patricia A. Daly, Mary B. Olopade, Olufunmilayo I. Tomlinson, Gail Schildkraut, Joellen Blum, Joanne L. Rebbeck, Timothy R. Amer medical assoc Chicago 645ad